Literature DB >> 17616522

Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.

Yuxian He1, Shuwen Liu, Weiguo Jing, Hong Lu, Dongmei Cai, Darin Jeekin Chin, Asim K Debnath, Frank Kirchhoff, Shibo Jiang.   

Abstract

The fusion-active HIV-1 gp41 core structure is a stable six-helix bundle (6-HB) formed by its N- and C-terminal heptad-repeat sequences (NHR and CHR). A highly conserved, deep hydrophobic cavity on the surface of the N-helical trimer is important for stability of the 6-HB and serves as an ideal target for developing anti-human immunodeficiency virus (HIV) fusion inhibitors. We have recently identified several small molecule HIV-1 fusion inhibitors that bind to the gp41 cavity through hydrophobic and ionic interactions and block the gp41 6-HB formation. Molecular docking analysis reveals that these small molecules fit inside the hydrophobic cavity and interact with positively charged residue Lys574 to form a conserved salt bridge. In this study, the functionality of Lys574 has been finely characterized by mutational analysis and biophysical approaches. We found that substitutions of Lys574 with non-conserved residues (K574D, K574E, and K574V) could completely abolish virus infectivity. With a set of wild-type and mutant N36 peptides derived from the NHR sequence as a model, we demonstrated that non-conservative Lys574 substitutions severely impaired the stability and conformation of 6-HBs as detected by circular dichroism spectroscopy, native polyacrylamide gel electrophoresis, and enzyme-linked immunosorbent assay. The binding affinity of N36 mutants bearing non-conservative Lys574 substitutions to the peptide C34 derived from the CHR sequence dramatically decreased as measured by isothermal titration calorimetry. These substitutions also significantly reduced the potency of N-peptides to inhibit HIV-1 infection. Collectively, these data suggest that conserved Lys574 plays a critical role in 6-HB formation and HIV-1 infectivity, and may serve as an important target for designing anti-HIV drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616522     DOI: 10.1074/jbc.M703781200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.

Authors:  Xiaowen Yu; Lu Lu; Lifeng Cai; Pei Tong; Suiyi Tan; Peng Zou; Fanxia Meng; Ying-Hua Chen; Shibo Jiang
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.

Authors:  Huihui Chong; Xue Yao; Zonglin Qiu; Bo Qin; Ruiyun Han; Sandro Waltersperger; Meitian Wang; Sheng Cui; Yuxian He
Journal:  J Biol Chem       Date:  2012-04-16       Impact factor: 5.157

3.  Structural basis of potent and broad HIV-1 fusion inhibitor CP32M.

Authors:  Xue Yao; Huihui Chong; Chao Zhang; Zonglin Qiu; Bo Qin; Ruiyun Han; Sandro Waltersperger; Meitian Wang; Yuxian He; Sheng Cui
Journal:  J Biol Chem       Date:  2012-06-07       Impact factor: 5.157

4.  Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.

Authors:  Dirk Eggink; Ilja Bontjer; Johannes P M Langedijk; Ben Berkhout; Rogier W Sanders
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

5.  Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41.

Authors:  Kun Liu; Hong Lu; Ling Hou; Zhi Qi; Cátia Teixeira; Florent Barbault; Bo-Tao Fan; Shuwen Liu; Shibo Jiang; Lan Xie
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

6.  Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.

Authors:  Yuxian He; Jianwei Cheng; Hong Lu; Jingjing Li; Jie Hu; Zhi Qi; Zhonghua Liu; Shibo Jiang; Qiuyun Dai
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

7.  DNA duplexes with hydrophobic modifications inhibit fusion between HIV-1 and cell membranes.

Authors:  Liang Xu; Lifeng Cai; Xueliang Chen; Xifeng Jiang; Huihui Chong; Baohua Zheng; Kun Wang; Junlin He; Wei Chen; Tao Zhang; Maosheng Cheng; Yuxian He; Keliang Liu
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

8.  A suite of modular fluorescence assays interrogate the human immunodeficiency virus glycoprotein-41 coiled coil and assist in determining binding mechanism of low molecular weight fusion inhibitors.

Authors:  Miriam Gochin
Journal:  Assay Drug Dev Technol       Date:  2012-08-16       Impact factor: 1.738

9.  The six-helix bundle of human immunodeficiency virus Env controls pore formation and enlargement and is initiated at residues proximal to the hairpin turn.

Authors:  Ruben M Markosyan; Michael Y Leung; Fredric S Cohen
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

10.  Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors.

Authors:  Zhi Qi; Weiguo Shi; Na Xue; Chungen Pan; Weiguo Jing; Keliang Liu; Shibo Jiang
Journal:  J Biol Chem       Date:  2008-07-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.